GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Read-Gene SA (WAR:RDG) » Definitions » Cyclically Adjusted Price-to-FCF

Read-Gene (WAR:RDG) Cyclically Adjusted Price-to-FCF : (As of May. 18, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Read-Gene Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Read-Gene Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Read-Gene's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Read-Gene Cyclically Adjusted Price-to-FCF Chart

Read-Gene Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Read-Gene Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Read-Gene's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Read-Gene's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Read-Gene's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Read-Gene's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Read-Gene's Cyclically Adjusted Price-to-FCF falls into.



Read-Gene Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Read-Gene's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Read-Gene's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.043/146.1131*146.1131
=-0.043

Current CPI (Sep. 2023) = 146.1131.

Read-Gene Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.006 101.018 0.009
201403 -0.004 101.262 -0.006
201406 -0.090 101.180 -0.130
201409 -0.002 100.611 -0.003
201412 0.090 100.122 0.131
201503 -0.064 100.041 -0.093
201506 -0.116 100.448 -0.169
201509 0.036 99.634 0.053
201512 0.015 99.471 0.022
201603 -0.037 98.983 -0.055
201606 0.063 99.552 0.092
201609 0.025 99.064 0.037
201612 -0.047 100.366 -0.068
201703 0.242 101.018 0.350
201706 -0.291 101.180 -0.420
201709 -0.059 101.343 -0.085
201712 0.060 102.564 0.085
201803 0.177 102.564 0.252
201806 0.025 103.378 0.035
201809 -0.036 103.378 -0.051
201812 -0.172 103.785 -0.242
201903 0.007 104.274 0.010
201906 -0.113 105.983 -0.156
201909 0.005 105.983 0.007
201912 -0.116 107.123 -0.158
202003 0.005 109.076 0.007
202006 -0.046 109.402 -0.061
202009 -0.010 109.320 -0.013
202012 0.078 109.565 0.104
202103 -0.021 112.658 -0.027
202106 -0.008 113.960 -0.010
202109 -0.032 115.588 -0.040
202112 0.070 119.088 0.086
202203 0.012 125.031 0.014
202206 -0.071 131.705 -0.079
202209 0.064 135.531 0.069
202212 0.025 139.113 0.026
202303 0.022 145.950 0.022
202306 -0.045 147.009 -0.045
202309 -0.043 146.113 -0.043

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Read-Gene  (WAR:RDG) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Read-Gene Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Read-Gene's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Read-Gene (WAR:RDG) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Ulica Alabastrowa 8, Grzepnica, Dobra, POL, 72-003
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.

Read-Gene (WAR:RDG) Headlines

No Headlines